Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2016', provides in depth analysis on Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted pipeline therapeutics. The report provides comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects - The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Overview 7 Therapeutics Development 8 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Stage of Development 8 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Therapy Area 9 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Indication 10 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Products under Development by Companies 13 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development 21 Astellas Pharma Inc. 21 Immunomic Therapeutics, Inc. 22 Vakzine Projekt Management GmbH 23 VBI Vaccines Inc 24 Vical Incorporated 25 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles 26 Anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 ASP-0113 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Cellular Immunotherpay to Target PP65 for Glioblastoma Multiforme - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CyMVectin - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 PepVax - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Triplex - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 VBI-1901 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 VPM-2001 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Projects 40 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products 41 Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Featured News & Press Releases 42 Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 42 Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 42 Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 43 Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 43 Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 44 Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 45 Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 46 Nov 20, 2015: VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology 47 Nov 06, 2015: VBI Vaccines to Present Update and New Data Supporting its CMV Vaccine Program at the World Vaccine Congress Europe 48 May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients 49 Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference 50 Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients 50 Jun 25, 2013: Vical And Astellas Initiate Phase III Trial Of ASP0113 Cytomegalovirus Vaccine 51 Apr 02, 2012: Astellas And Vical Advance Toward Phase III Trial Of TransVax CMV Vaccine Triggering $10m Milestone Payment To Vical 51 Jan 11, 2012: Vical Provides Update On CyMVectin Prophylactic Vaccine 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Astellas Pharma Inc., H2 2016 21 Pipeline by Immunomic Therapeutics, Inc., H2 2016 22 Pipeline by Vakzine Projekt Management GmbH, H2 2016 23 Pipeline by VBI Vaccines Inc, H2 2016 24 Pipeline by Vical Incorporated, H2 2016 25 Dormant Projects, H2 2016 40 Discontinued Products, H2 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
